Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
about
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasCD19 as an attractive target for antibody-based therapyAntigenic modulation and rituximab resistance.Nanofibrous lipid membranes capable of functionally immobilizing antibodies and capturing specific cells.Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomasAdministration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effectsThe HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumorsSuccessful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8bChemotherapy and tumor immunity: an unexpected collaborationDual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphomaDrug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric NanomedicinesInhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.Gamma-retroviral vectors enveloped with an antibody and an engineered fusogenic protein achieved antigen-specific targeting.CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.Monoclonal antibodies for cancer immunotherapy.Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.A Case of Chronic Conjunctivitis following Rituximab TherapyTranslational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.CD19-CAR trials.PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms.Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.Three major uncertainties in the antibody therapy of cancer.Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapyStructurally Defined αMHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma.A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicityExceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.Disease progression after R-CHOP treatment associated with the loss of CD20 antigen expression.Immunotherapy for B-cell lymphoma: current status and prospective advancesA comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia.Immunophenotype evaluation of Non-Hodgkin's lymphomas.
P2860
Q26751002-7409FC3C-E0A2-4858-B980-8E5F44EA237FQ27011836-E46BABBB-2390-4426-A844-F89F98EDE855Q30432874-67F6E9F1-056F-4257-BD88-DB9FB3671EB4Q30504484-D1295811-2865-4A0B-B3F7-411AE213655EQ30867713-A57248C8-B8A9-4522-B547-AF45D5F5DE8AQ33905411-9D331C05-ACFF-4C7B-B109-3383C8DDE409Q33913962-07F26231-01CC-46EC-807F-4D7B6B5B1B47Q33993679-DCA74458-AB63-43BC-9BF1-8CBA30708FB5Q34116916-9674D29C-908B-471E-8690-7B8AFA0B61F5Q34909777-55CE15FC-872C-42A2-9FAB-8AEB59328269Q35035048-7FCFB8B6-C029-404A-B5C0-33FDF0E4A4FCQ35783537-C50BB432-2F59-4703-A090-3FDAFD0863B4Q35861726-9D0DB982-143C-43D9-9EA4-E18107EDE824Q36213094-15D8100D-D6CE-4464-857B-53F059F2E5D3Q36923861-58E65051-1DCB-408B-8687-7F1B86F78927Q37112898-11186173-6829-493E-ACDD-038C52C8202EQ37181031-1AED744B-7CD2-4FE1-8CCD-E66261163AC4Q37280910-86F2D5F2-9816-47C2-9F08-0D6CCDF8DE44Q37424763-DCDEDFD4-7718-4EB6-9C3F-97607DB89C0FQ37552017-B22C23BF-78F9-4A88-A115-B17FC75BC127Q37672472-185E40AB-D05F-4E7F-A1B3-8C153A499738Q37692134-9EE5DB26-CD51-4EF3-A089-88A726EEF843Q37775841-157F85B4-558D-41FE-B5FD-5E2CCBCE664DQ37793222-71B12841-0B2B-4F3B-81C8-FFFE63E6D929Q37819809-273C251F-D267-47C7-8648-2DB1B91434DFQ38255786-B224FD7B-4971-4047-869B-5CD37FA4695AQ38759420-45FFE619-8556-4183-819E-611860DFD1EFQ38797038-72B4E12B-F8D0-4603-8020-28B14A143736Q39004366-BA814253-EA47-4ACD-8057-DCEAD676E7EBQ39306456-77D1461F-2522-45CC-85F3-61BBE07C6884Q40490888-C5046795-9032-43C7-A915-3E56AD3EA433Q41823493-2F340265-D712-4A15-B7D2-A0D9DA6E14B0Q41831989-64D28A25-A3C1-4258-8914-04CB7CCE0753Q49177202-AA6E4653-279A-4711-9C9F-BD6D3D9731B9Q50017171-59E45F57-3303-47DB-A0C1-A6A05F45FEC7Q53758334-429B5290-62A9-48FC-BDF0-7792F9BDC681Q55385039-C1B1A691-CA72-42ED-8272-65E206BEEDC4
P2860
Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@ast
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@en
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@nl
type
label
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@ast
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@en
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@nl
prefLabel
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@ast
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@en
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@nl
P2093
P1476
Therapy of B-cell lymphoma wit ...... ss of CD20 antigen expression.
@en
P2093
P304
P407
P577
1999-03-01T00:00:00Z